Kavakli Kaan, Yilmaz Deniz, Cetinkaya Bilin, Balkan Can, Sözmen Eser Yildirim, Sağin Ferhan Girgin
Department of Pediatric Hematology, Ege University Faculty of Medicine, Izmir, Turkey.
Pediatr Hematol Oncol. 2004 Jul-Aug;21(5):403-10. doi: 10.1080/08880010490457114.
The major purpose of this study was to compare the oxidant-related toxicities of the different oral iron preparations in children with iron deficiency anemia (IDA); the second aim was to investigate the side effects of iron preparations. Seventy-two children with IDA were randomly included in the Fe(2+) group (n = 39) or the Fe(3+) group (n = 33). Some oxidizable substrates (erythrocytes malondialdehyde (MDA), urine 8-isoprostane, and basal and Cu-stimulated-oxidized LDL and antioxidant enzyme (superoxide dismutase (SOD), catalase and glutathione peroxidase) activities were evaluated at the beginning and at the 1st, 3rd, and 6th months of therapy. Side effects due to medication were recorded. While at the end of the 1st month SOD levels were significantly increased in Fe(3+) group, at the 6th month evaluation, basal-oxidized LDL levels were significantly increased in the Fe(3+) group, as was urine 8-isoprostane in the Fe(2+) group. No other difference was found between two groups. In conclusion, there were minimal differences between children treated with ferric or ferrous iron in antioxidant system activities, the status of oxidizable substrates, and clinical toxicities.
本研究的主要目的是比较不同口服铁制剂对缺铁性贫血（IDA）患儿的氧化相关毒性；第二个目的是调查铁制剂的副作用。72例IDA患儿被随机纳入亚铁组（n = 39）或高铁组（n = 33）。在治疗开始时以及治疗的第1、3和6个月评估一些可氧化底物（红细胞丙二醛（MDA）、尿8-异前列腺素、基础及铜刺激氧化型低密度脂蛋白）和抗氧化酶（超氧化物歧化酶（SOD）、过氧化氢酶和谷胱甘肽过氧化物酶）活性。记录药物引起的副作用。在第1个月末，高铁组的SOD水平显著升高，在第6个月评估时，高铁组的基础氧化型低密度脂蛋白水平显著升高，亚铁组的尿8-异前列腺素水平也显著升高。两组之间未发现其他差异。总之，在抗氧化系统活性、可氧化底物状态和临床毒性方面，接受三价铁或二价铁治疗的儿童之间差异极小。
